It may be hard to remember now, but when 2020 began, there was speculation that there could be major drug pricing legislation in a post-Election Lame Duck session.
There was some logic to the idea back in January and February
Rebate Reporting Law May Provide Timely Trigger For US Pricing Debate – In 2023
Newly enacted requirement for US health plans to report granular drug price and rebating data to the government suggests that the great rebate debate of 2017-2020 won’t be over for long. The first public release of aggregated data will likely come in 2023 – and that might be when Congress is ready to take up drug pricing again.
